Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria

J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1659-1661.e1. doi: 10.1016/j.jaip.2018.11.018. Epub 2018 Nov 27.

Authors

Jason Kihyuk Lee¹, Rachel S Simpson²

Affiliations

¹ Evidence Based Medical Educator Inc, Toronto, Ontario, Canada.
² Evidence Based Medical Educator Inc, Toronto, Ontario, Canada; Urticaria Canada, Toronto, Ontario, Canada; Division of Life Sciences, Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada. Electronic address: rachel.simpson@queensu.ca.

PMID: 30496828
DOI: 10.1016/j.jaip.2018.11.018

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Chronic Urticaria*
Humans
Omalizumab
Urticaria*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Omalizumab
dupilumab